Across TCGA pan-cancer cohorts, PMS2CL Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PMS2CL data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PMS2CL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PMS2CL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and LUAD are the cancer types where PMS2CL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.265	0.646	.022	6	view →
UCEC	DFS	Median	II,III,IV	0.922	0.436	.022	6	view →
LUAD	DFS	Median	All	0.259	0.679	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PMS2CL tumor-vs-normal RNA expression · all PMS2CL data types